VJOncology is committed to improving our service to you

ASCO 2020 | ARROW study: pralsetinib in RET fusion+ tumors

VJOncology is committed to improving our service to you

Vivek Subbiah

Vivek Subbiah, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the ARROW study (NCT03037385), which aimed to test the activity of pralsetinib, a selective inhibitor of oncogenic RET alterations in solid tumours. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter